Apr 12, 2016

Posted by in Biotech Stocks | 0 Comments

Stocks Buzz: Novavax Inc (NASDAQ:NVAX), Celgene Corporation (NASDAQ:CELG), Clovis Oncology Inc (NASDAQ:CLVS)

Stocks Buzz: Novavax Inc (NASDAQ:NVAX), Celgene Corporation (NASDAQ:CELG), Clovis Oncology Inc (NASDAQ:CLVS)

Novavax Inc (NASDAQ:NVAX) stock is at $5.47, down -0.73 percent from its previous close of $5.51. The stock opened the session at $5.58 and touched its highest price point at $5.75. The company’s stock’s lowest price point for the session stood at $5.45. Its yesterday’s volume was 4.99 million shares in comparison to its usual trading volume of 6.54 million shares.

Novavax Inc (NASDAQ:NVAX) on April 4, 2016 announced that Iksung Cho has been named Vice President, Biostatistics.

Mr. Cho joined Novavax in December 2015 as Executive Director, Biostatistics with responsibility for coordinating statistical and statistical programming activities for vaccine candidates in various stages of clinical development. Prior to joining Novavax he was Senior Statistician at PATH, an international nonprofit organization that aims to accelerate innovation across vaccines, drugs, diagnostics, devices and system and service innovations.

Mr. Cho’s experience includes positions of increasing responsibility in biostatistics and data management at Aviron, Merck and MedImmune, where he was Vice President of Global Biostatistics. He earned Master’s degrees in both statistics and applied mathematics from Virginia Polytechnic and State University and completed graduate studies in mathematics.

Celgene Corporation (NASDAQ:CELG) stock is at $103.81, down -2.31 percent from its previous close of $106.26. Its yesterday’s volume was 4.85 million shares in comparison to its usual trading volume of 5.49 million shares. Previous 5 days graph demonstrated a positive move of 2.73%. Its quarterly performance remained green with the percentage of 0.76, while its year to date performance showed that the stock plunged overall -13.98%.

Celgene Corporation (NASDAQ:CELG) on April 1, 2016 announced that the company will host a conference call and live audio webcast on Thursday, April 28, 2016 at 9 a.m. ET to discuss first quarter 2016 financial and operational results.

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation.

Clovis Oncology Inc (NASDAQ:CLVS) traded in the range of $14.38 and $16.05 in its previous trading session. The stock recorded the volume of 4.75 million shares so far, in comparison its average daily trading volume of 1.42 million shares. Company’s year to date performance remained declining as it lost almost -56.22%. The stock opened at $15.97 and its closing price for the day was $15.06, down -4.50 percent from its previous close.

Clovis Oncology Inc (NASDAQ:CLVS)  on February 25, 2016 reported a net loss for the fourth quarter of 2015 of $119.5 million ($3.12) per share, and $352.9 million ($9.79) per share for the year ended December 31, 2015. Importantly, the net loss for the fourth quarter and full year 2015 includes a $89.6 million non-cash charge ($61.0 million net of the related income tax benefit) for the impairment of the intangible asset relating to the lucitanib product rights recorded in 2013 in connection with the Company’s acquisition of Ethical Oncology Science S.p.A. (EOS) and a $26.9 million non-cash expense credit for the reduction in the fair value of the contingent purchase considerations liability, also related to the EOS acquisition. The adjusted net loss excluding these items was $85.4 million ($2.23 per share) in the fourth quarter of 2015 and $318.8 million ($8.85 per share) for the year ended December 31, 2015. The net loss for the fourth quarter of 2014 was $54.9 million ($1.62 per share) and $160.0 million ($4.72 per share) for the year ended December 31, 2014.

 

Comments are closed.